Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

• Kaleen N. Hayes,
• Ulrike Baschant,
• Barbara Hauser,
• Barbara Hauser,
• Andrea M. Burden,
• Elizabeth M. Winter

Affiliations

Kaleen N. Hayes

Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States

Ulrike Baschant

Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Barbara Hauser

Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom

Barbara Hauser

Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom

Andrea M. Burden

Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland

Elizabeth M. Winter

Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands